| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$10,903 ) |
| | 2024 | 2022 | HJARTAVERND SES | HOLTASMARA 1 | KOPAVOGI | | | | ISL | R01AG065596 | Serum proteome analysis of Alzheimer?s disease in a population-based longitudinal cohort study - the AGES Reykjavik study | 000 | 2 | NIH | 12/14/2023 | -$10,903 |
|
| Issue Date FY: 2022 ( Subtotal = $704,486 ) |
| | 2022 | 2022 | HJARTAVERND SES | HOLTASMARA 1 | KOPAVOGI | | | | ISL | R01AG065596 | Serum proteome analysis of Alzheimer?s disease in a population-based longitudinal cohort study - the AGES Reykjavik study | 000 | 2 | NIH | 5/11/2022 | $704,486 |
|
| Issue Date FY: 2021 ( Subtotal = $712,883 ) |
| | 2021 | 2021 | ICELANDIC HEART ASSOCIATION | 1 | KOPAVOGI | | | | ISL | R01AG065596 | Serum proteome analysis of Alzheimer?s disease in a population-based longitudinal cohort study - the AGES Reykjavik study | 000 | 1 | NIH | 4/9/2021 | $712,883 |
|
|
